



# ECIBC recommendation on staging breast cancer with PET-CT at clinical stage III

## Bibliography

### Evidence of effects

Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. *J Nucl Med*. 2009 Feb;50(2):231-8

Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubreau M, et al. 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. *Eur J Nucl Med Mol Imaging*. 2014 Mar;41(3):428-37

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, et al. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. *J Natl Cancer Inst*. 2012 Dec 19;104(24):1879-87

Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. *Int J Radiat Oncol Biol Phys*. 2008 Jul 1;71(3):695-704

Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gonen M, Osborne JR, et al. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. *J Nucl Med*. 2015 Nov;56(11):1674-80

Krammer J, Schnitzer A, Kaiser CG, Buesing KA, Sperk E, Brade J, et al. (18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?. *Eur Radiol*. 2015 Aug;25(8):2460-9.

Lebon V, Alberini JL, Pierga, JY, Dieras V, Jehanno N, Wartski M. Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years. *J Nucl Med*. 2017 Feb;58(2):252-257

Manohar K, Mittal BR, Bhoil A, Bhattacharya A, Singh G. Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer. *Nucl Med Commun*. 2013 Jun;34(6):557-61

Ng SP, David S, Alamgeer M, Ganju V. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer. *Int J Radiat Oncol Biol Phys*. 2015 Sep 1;93(1):111-7.

Reddy Akepati NK, Abubakar ZA, Bikkina P. Role of 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Scan in Primary Staging of Breast Cancer Compared to Conventional Staging. *Indian J Nucl Med*. 2018 Jul-Sep;33(3):190-193.

Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. *J Nucl Med*. 2014 Oct;55(10):1578-83



Sen F, Akpınar AT, Ogur U, Duman G, Tamgac F, Alper E. The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients. Nucl Med Commun. 2013 Jun;34(6):571-6.

Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, et al. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1937-44.

Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1420-1427

### **Resources required**

Koleva-Kolarova RG, Greuter MJ, van Kruchten M, Vermeulen KM, Feenstra T, Buskens E, et al. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. Br J Cancer. 2015 May 12;112(10):1617-25